Free Trial

Eli Lilly and Company (LLY) Competitors

$900.69
+16.81 (+1.90%)
(As of 12:37 PM ET)

LLY vs. JNJ, MRK, ABBV, PFE, BMY, ZTS, RPRX, JAZZ, PRGO, and CORT

Should you be buying Eli Lilly and Company stock or one of its competitors? The main competitors of Eli Lilly and Company include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), AbbVie (ABBV), Pfizer (PFE), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), and Corcept Therapeutics (CORT). These companies are all part of the "pharmaceuticals" industry.

Eli Lilly and Company vs.

Johnson & Johnson (NYSE:JNJ) and Eli Lilly and Company (NYSE:LLY) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, community ranking, dividends, media sentiment, risk, valuation and institutional ownership.

Johnson & Johnson pays an annual dividend of $4.96 per share and has a dividend yield of 3.3%. Eli Lilly and Company pays an annual dividend of $5.20 per share and has a dividend yield of 0.6%. Johnson & Johnson pays out 30.9% of its earnings in the form of a dividend. Eli Lilly and Company pays out 76.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Johnson & Johnson has increased its dividend for 63 consecutive years. Johnson & Johnson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Eli Lilly and Company received 86 more outperform votes than Johnson & Johnson when rated by MarketBeat users. Likewise, 70.13% of users gave Eli Lilly and Company an outperform vote while only 65.04% of users gave Johnson & Johnson an outperform vote.

CompanyUnderperformOutperform
Johnson & JohnsonOutperform Votes
1090
65.04%
Underperform Votes
586
34.96%
Eli Lilly and CompanyOutperform Votes
1176
70.13%
Underperform Votes
501
29.87%

Johnson & Johnson has higher revenue and earnings than Eli Lilly and Company. Johnson & Johnson is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Johnson & Johnson$85.16B4.20$35.15B$16.049.27
Eli Lilly and Company$34.12B24.62$5.24B$6.79130.17

Johnson & Johnson has a net margin of 45.26% compared to Johnson & Johnson's net margin of 17.08%. Johnson & Johnson's return on equity of 56.98% beat Eli Lilly and Company's return on equity.

Company Net Margins Return on Equity Return on Assets
Johnson & Johnson45.26% 36.70% 15.07%
Eli Lilly and Company 17.08%56.98%10.94%

Johnson & Johnson has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500. Comparatively, Eli Lilly and Company has a beta of 0.36, suggesting that its share price is 64% less volatile than the S&P 500.

In the previous week, Eli Lilly and Company had 16 more articles in the media than Johnson & Johnson. MarketBeat recorded 51 mentions for Eli Lilly and Company and 35 mentions for Johnson & Johnson. Johnson & Johnson's average media sentiment score of 0.65 beat Eli Lilly and Company's score of 0.64 indicating that Eli Lilly and Company is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Johnson & Johnson
14 Very Positive mention(s)
7 Positive mention(s)
9 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Positive
Eli Lilly and Company
24 Very Positive mention(s)
12 Positive mention(s)
7 Neutral mention(s)
3 Negative mention(s)
2 Very Negative mention(s)
Positive

Johnson & Johnson presently has a consensus price target of $174.07, suggesting a potential upside of 17.02%. Eli Lilly and Company has a consensus price target of $803.50, suggesting a potential downside of 9.09%. Given Eli Lilly and Company's higher possible upside, equities analysts clearly believe Johnson & Johnson is more favorable than Eli Lilly and Company.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Johnson & Johnson
0 Sell rating(s)
8 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.38
Eli Lilly and Company
0 Sell rating(s)
3 Hold rating(s)
16 Buy rating(s)
0 Strong Buy rating(s)
2.84

69.6% of Johnson & Johnson shares are owned by institutional investors. Comparatively, 82.5% of Eli Lilly and Company shares are owned by institutional investors. 0.2% of Johnson & Johnson shares are owned by company insiders. Comparatively, 0.1% of Eli Lilly and Company shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Johnson & Johnson beats Eli Lilly and Company on 11 of the 21 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LLY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LLY vs. The Competition

MetricEli Lilly and CompanyPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$840.05B$6.86B$4.93B$17.78B
Dividend Yield0.59%2.76%5.25%3.62%
P/E Ratio130.1721.32160.9724.28
Price / Sales24.62241.322,242.6714.57
Price / Cash116.1731.7932.5819.17
Price / Book77.265.654.754.56
Net Income$5.24B$143.99M$105.56M$971.75M
7 Day Performance-0.13%3.62%116.62%1.88%
1 Month Performance9.47%0.55%115.19%-0.50%
1 Year Performance92.63%-5.85%122.65%11.76%

Eli Lilly and Company Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
JNJ
Johnson & Johnson
4.7682 of 5 stars
$145.65
-0.2%
$174.07
+19.5%
-10.1%$350.53B$85.16B9.08131,900Analyst Downgrade
MRK
Merck & Co., Inc.
4.4484 of 5 stars
$127.99
+0.4%
$133.00
+3.9%
+14.1%$324.17B$60.12B142.2172,000Positive News
ABBV
AbbVie
4.6651 of 5 stars
$171.35
+1.0%
$179.64
+4.8%
+25.4%$302.58B$54.32B50.8550,000Dividend Announcement
PFE
Pfizer
4.7979 of 5 stars
$27.41
+1.6%
$35.86
+30.8%
-27.6%$155.32B$58.50B-456.7688,000
BMY
Bristol-Myers Squibb
4.7996 of 5 stars
$40.82
-0.4%
$60.00
+47.0%
-35.5%$82.75B$45.01B-13.1734,100Dividend Announcement
ZTS
Zoetis
4.8258 of 5 stars
$169.66
-0.7%
$211.75
+24.8%
+1.6%$77.42B$8.54B32.6914,100Positive News
RPRX
Royalty Pharma
4.894 of 5 stars
$26.26
-1.3%
$43.00
+63.7%
-13.1%$15.69B$2.36B19.6051Positive News
JAZZ
Jazz Pharmaceuticals
4.8976 of 5 stars
$112.68
-1.6%
$190.92
+69.4%
-13.5%$7.10B$3.83B23.232,800Positive News
PRGO
Perrigo
4.9847 of 5 stars
$25.55
-2.6%
$39.67
+55.3%
-23.1%$3.48B$4.66B-365.009,140
CORT
Corcept Therapeutics
4.8248 of 5 stars
$28.15
-1.5%
$44.30
+57.4%
+37.4%$2.93B$482.38M26.56352

Related Companies and Tools

This page (NYSE:LLY) was last updated on 6/24/2024 by MarketBeat.com Staff

From Our Partners